Antares Pharma Inc. (ATRS)

3.26
NASDAQ : Health Technology
Prev Close 3.37
Day Low/High 3.24 / 3.40
52 Wk Low/High 1.58 / 4.09
Avg Volume 1.10M
Exchange NASDAQ
Shares Outstanding 157.44M
Market Cap 530.56M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Antares Pharma Reports Fourth Quarter And Full Year 2017 Operating And Financial Results

Antares Pharma Reports Fourth Quarter And Full Year 2017 Operating And Financial Results

Record Annual Revenue of $54.5 Million

First Week of April 20th Options Trading For Antares Pharma (ATRS)

First Week of April 20th Options Trading For Antares Pharma (ATRS)

Investors in Antares Pharma Inc. saw new options become available this week, for the April 20th expiration.

Antares Pharma Announces FDA Approval Of Partner's Product Utilizing Our QuickShot Auto Injector

Antares Pharma Announces FDA Approval Of Partner's Product Utilizing Our QuickShot Auto Injector

AMAG Pharmaceuticals Makena® Subcutaneous Auto-Injector Approved To Reduce The Risk Of Preterm Birth In Certain At-Risk Women

Antares Pharma Announces FDA Approval Of Partner's Product Utilizing Our QuickShot Auto Injector

Antares Pharma Announces FDA Approval Of Partner's Product Utilizing Our QuickShot Auto Injector

AMAG Pharmaceuticals Makena® Subcutaneous Auto-Injector Approved To Reduce The Risk Of Preterm Birth In Certain At-Risk Women

Glancy Prongay & Murray Reminds Investors Of The December 22, 2017 Deadline In The Class Action Lawsuit Against Antares Pharma, Inc. (ATRS)

Glancy Prongay & Murray Reminds Investors Of The December 22, 2017 Deadline In The Class Action Lawsuit Against Antares Pharma, Inc. (ATRS)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the December 22, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Antares Pharma, Inc.

ANTARES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Antares Pharma, Inc. To Contact The Firm

ANTARES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Antares Pharma, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Antares Pharma, Inc.

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of December 22nd Lead Plaintiff Deadline In Securities Class Action Against Antares Pharma, Inc. (ATRS)

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of December 22nd Lead Plaintiff Deadline In Securities Class Action Against Antares Pharma, Inc. (ATRS)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Antares Pharma, Inc.

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

ATRS LOSS NOTICE: Rosen Law Firm Reminds Antares Pharma, Inc. Investors Of Important Deadline In Class Action

ATRS LOSS NOTICE: Rosen Law Firm Reminds Antares Pharma, Inc. Investors Of Important Deadline In Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Antares Pharma, Inc.

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Antares Pharma, Inc. Shareholders And A Lead Plaintiff Deadline Of December 22, 2017

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Antares Pharma, Inc. Shareholders And A Lead Plaintiff Deadline Of December 22, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Antares Pharma, Inc.

ATRS INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Antares Pharma, Inc. And A Lead Plaintiff Deadline Of December 22, 2017

ATRS INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Antares Pharma, Inc. And A Lead Plaintiff Deadline Of December 22, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Antares Pharma, Inc.

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Antares Pharma, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of December 22, 2017

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Antares Pharma, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of December 22, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Antares Pharma, Inc.

Exiting 2 Pharmaceutical Positions

We'd rather get ahead of that coming wave of year-end tax loss selling.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Antares Pharma, Inc. - ATRS

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Antares Pharma, Inc. - ATRS

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Antares Pharma, Inc.

The Klein Law Firm Announces A Class Action Filed On Behalf Of Antares Pharma, Inc. Shareholders And A Lead Plaintiff Deadline Of December 22, 2017

The Klein Law Firm Announces A Class Action Filed On Behalf Of Antares Pharma, Inc. Shareholders And A Lead Plaintiff Deadline Of December 22, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Antares Pharma, Inc.

ATRS INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Antares Pharma, Inc. And A Lead Plaintiff Deadline Of December 22, 2017

ATRS INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Antares Pharma, Inc. And A Lead Plaintiff Deadline Of December 22, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Antares Pharma, Inc.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Antares Pharma, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

Antares Pharma Reports Third Quarter 2017 Operating And Financial Results

Antares Pharma Reports Third Quarter 2017 Operating And Financial Results

Record Quarterly Revenue of $15.1 Million and Net Loss Per Share of $0.03

Stocks Under $10 Weekly Summary

Last week, we increased our holdings in one position and added 2 Bullpen names.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Antares Pharma, Inc.

TheStreet Quant Rating: D (Sell)